



ORGANAMET BIO

For immediate release: October 16, 2022
www.OrganametBio.com

Organamet Bio continues to watch and support the desire to solve the unmet need for hearts for transplant. The recent article by Dr. Megan Sykes in Science (Section Perspective | Medicine) suggesting that pig hearts may solve the unmet need for organs reillustrates the dramatic unmet need and the current willingness to accept imperfect solutions. As indicated earlier this year - the transplant of a pig heart into a heart failure patient who otherwise could not receive a human heart transplant was a groundbreaking accomplishment and a long-awaited culmination of a 40-year discovery process. We, like everyone, welcome the breaking down of barriers this accomplished and the predicate it set.

This step forward demonstrates the huge unmet need: So few human hearts are available that patients are willing to receive a pig heart, not knowing if or how long it may last. It also shows the promise of regenerative medicine in solving the unmet need for organs for transplant. Dr. Doris Taylor, CEO of Organamet Bio, stated, “A pig heart transplant has been anticipated for a few years now –and is a thrill to see. At the same time, the need for immunosuppression to prevent rejection remains a major financial and medical hurdle for these patients. We all greatly look forward to the day enough human hearts are available for transplant. The world of regenerative medicine is rapidly accelerating, and Organamet Bio is thrilled to be a contributor to the future that includes bioengineering autologous human hearts that will overcome these final hurdles to having enough organs to treat the No. 1 killer of men, women, and children worldwide.”

Organamet Bio Inc., with R&D and manufacturing headquartered in Manchester, NH, at ARMI | BioFabUSA, is developing autologous human hearts (Your-Heart™ Solution) to be used for transplant. Your-Heart™ Solution takes heart transplant from a time-constrained emergency surgery to a scheduled procedure. It also eliminates the need for anti-rejection drugs, reduces patient costs, and, more importantly, extends patients’ lives. The company has assembled an international team, including the technology inventor whose prior company successfully exited earlier this year, with global leaders in regenerative medicine, cardiovascular disease, biotech manufacturing, and intellectual property.

Organamet Bio Inc. is a strategic partner of the Advanced Regenerative Manufacturing Institute (ARMI). ARMI is a member-based, non-profit organization funded by the United States Department of Defense. ARMI’s mission is to make practical the scalable, consistent, and cost-effective manufacturing of tissue-engineered medical products and tissue-related technologies.